Literature DB >> 11927164

Two alpha(2)-adrenergic receptor subtypes, alpha(2A) and alpha(2C), inhibit transmitter release in the brain of gene-targeted mice.

M M Bücheler1, K Hadamek, L Hein.   

Abstract

alpha(2)-Adrenergic receptors play an essential role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the CNS. However, the role of each of the three highly homologous alpha(2)-adrenergic receptor subtypes (alpha(2A), alpha(2B), alpha(2C)) in this process has not been determined unequivocally. To address this question, the regulation of norepinephrine and dopamine release was studied in mice carrying deletions in the genes encoding the three alpha(2)-adrenergic receptor subtypes. Autoradiography and radioligand binding studies showed that alpha(2)-receptor density in alpha(2A)-deficient brains was decreased to 9 +/- 1% of the respective wild-type value, whereas alpha(2)-receptor levels were reduced to 83 +/- 4% in alpha(2C)-deficient mice. These results indicate that approximately 90% of mouse brain alpha(2)-receptors belong to the alpha(2A) subtype and 10% are alpha(2C)-receptors. In isolated brain cortex slices from wild-type mice a non-subtype-selective alpha(2)-receptor agonist inhibited release of [(3)H]norepinephrine by maximally 96%. Similarly, release of [(3)H]dopamine from isolated basal ganglion slices was inhibited by 76% by an alpha(2)-receptor agonist. In alpha(2A)-receptor-deficient mice, the inhibitory effect of the alpha(2)-receptor agonist on norepinephrine and dopamine release was significantly reduced but not abolished. Only in tissues from mice lacking both alpha(2A)- and alpha(2C)-receptors was no alpha(2)-receptor agonist effect on transmitter release observed. The time course of onset of presynaptic inhibition of norepinephrine release was much faster for the alpha(2A)-receptor than for the alpha(2C)-subtype. After prolonged stimulation with norepinephrine, presynaptic alpha(2C)-adrenergic receptors were desensitized. From these data we suggest that two functionally distinct alpha(2)-adrenergic receptor subtypes, alpha(2A) and alpha(2C), operate as presynaptic inhibitory receptors regulating neurotransmitter release in the mouse CNS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927164     DOI: 10.1016/s0306-4522(01)00531-0

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  36 in total

1.  Role of adrenoceptors in the regulation of dopamine/DARPP-32 signaling in neostriatal neurons.

Authors:  Masato Hara; Ryuichi Fukui; Eriko Hieda; Mahomi Kuroiwa; Helen S Bateup; Tatsuhiko Kano; Paul Greengard; Akinori Nishi
Journal:  J Neurochem       Date:  2010-03-04       Impact factor: 5.372

2.  Neuron specific alpha-adrenergic receptor expression in human cerebellum: implications for emerging cerebellar roles in neurologic disease.

Authors:  U B Schambra; G B Mackensen; M Stafford-Smith; D E Haines; D A Schwinn
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

3.  JP-1302: a new tool to shed light on the roles of alpha2C-adrenoceptors in brain.

Authors:  M D Tricklebank
Journal:  Br J Pharmacol       Date:  2007-01-15       Impact factor: 8.739

4.  Distinct mixtures of muscarinic receptor subtypes mediate inhibition of noradrenaline release in different mouse peripheral tissues, as studied with receptor knockout mice.

Authors:  Anne-Ulrike Trendelenburg; Angelika Meyer; Jürgen Wess; Klaus Starke
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

5.  Immunohistochemical localization of α2-adrenergic receptors in the neonatal rat cochlea and the vestibular labyrinth.

Authors:  Jing Cai; Jianfeng Li; Yanyan Mao; Xiaohui Bai; Lei Xu; Haibo Wang
Journal:  J Mol Neurosci       Date:  2013-08-22       Impact factor: 3.444

Review 6.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

7.  Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.

Authors:  Corinne Y Ostock; Joy Hallmark; Noel Palumbo; Nirmal Bhide; Melissa Conti; Jessica A George; Christopher Bishop
Journal:  Neuropharmacology       Date:  2015-03-25       Impact factor: 5.250

8.  The alpha2-adrenoceptor antagonist atipamezole reduces the development and expression of d-amphetamine-induced behavioural sensitization.

Authors:  Juuso Juhila; Antti Haapalinna; Jouni Sirviö; Jukka Sallinen; Aapo Honkanen; Esa R Korpi; Mika Scheinin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-14       Impact factor: 3.000

9.  Interdependent adrenergic receptor regulation of Arc and Zif268 mRNA in cerebral cortex.

Authors:  Norah Essali; Jeff Sanders
Journal:  Neurosci Lett       Date:  2015-12-03       Impact factor: 3.046

10.  The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats.

Authors:  Antti Haapalinna; Tiina Leino; Esa Heinonen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-18       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.